Optimization of methazolamide-loaded solid lipid nanoparticles for ophthalmic delivery using Box-Behnken design

Journal of Liposome Research

Volumn 24, Issue 3, 2014, Pages 171-181

  Wang, Fengzhen ^a,b   Chen, Li ^a   Jiang, Sunmin ^a   He, Jun ^a   Zhang, Xiumei ^a   Peng, Jin ^c   Xu, Qunwei ^a   Li, Rui ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Box Behnken design; Emulsion solvents evaporation; Methazolamide; Solid lipid nanoparticles

Indexed keywords

BRINZOLAMIDE; EYE DROPS; MACROGOL 400; METHAZOLAMIDE; PHOSPHOLIPID; POLYSORBATE 80; SOLID LIPID NANOPARTICLE; LIPOSOME; MACROGOL DERIVATIVE; NANOPARTICLE; POLYSORBATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; BOX BEHNKEN DESIGN; CONTROLLED STUDY; DEPENDENT VARIABLE; EYE IRRITATION; FEMALE; IN VIVO STUDY; INDEPENDENT VARIABLE; INFRARED SPECTROSCOPY; INTRAOCULAR PRESSURE; LOW TEMPERATURE; MALE; MORPHOLOGY; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROCESS DESIGN; REVIEW; SUSTAINED DRUG RELEASE; ZETA POTENTIAL; ANIMAL; CHEMICALLY INDUCED; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; ENDOPHTHALMITIS; HUMAN; PROCEDURES; RABBIT; SYNTHESIS; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANIMALS; DRUG DELIVERY SYSTEMS; ENDOPHTHALMITIS; FEMALE; HUMANS; INTRAOCULAR PRESSURE; LIPOSOMES; MALE; METHAZOLAMIDE; NANOPARTICLES; OPHTHALMIC SOLUTIONS; PARTICLE SIZE; POLYETHYLENE GLYCOLS; POLYSORBATES; RABBITS;

EID: 84906282106     PISSN: 08982104     EISSN: 15322394     Source Type: Journal    
DOI: 10.3109/08982104.2014.891231     Document Type: Review

References (41)

1. Atkinson AC, Donev AN. (1992). Optimum experimental designs. Oxford: Oxford University Press.
2. Batistuti JP, Barros RMC, Areas JAG. (1991). Optimization of extrusion cooking process for chickpea (Cicer arietinum, L.) defatted flour by response surface methodology. J Food Sci 56:1695-8.
3. Bourlals C, Acar L, Zia H, et al. (1998). Ophthalmic drug delivery systems recent advances. Prog Retin Eye Res 17:33-58.
4. Budhian A, Siegel SJ, Winey KI. (2007). Haloperidol-loaded PLGA nanoparticles: systematic study of particle size and drug content. Int J Pharm 336:367-75.
5. Chang J, Huang Y, Hou S, et al. (2007). Formulation optimization of meloxicam sodium gel using response surface methodology. Int J Pharm 338:48-54.
6. De Santis L. (2000). Preclinical overview of brinzolamide. Surv Ophthalmol 44:119-29.
7. Dong C-H, Xie XQ, Wang XL, et al. (2009). Application of Box-Behnken design in optimisation for polysaccharides extraction from cultured mycelium of cordyceps sinensis. Food Bioprod Process 87:139-44.
8. Draize JH, Woodard G, Calvery HO. (1994). Method for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J Pharmacol Exp Ther 82:377-90.
9. El-Malah Y, Nazzal S, Khanfar N. (2006). D-optimal mixture design: optimization of ternary matrix blends for controlled zeroorder drug release from oral dosage forms. Drug Dev Ind Pharm 32: 1207-18.
10. Epstein DL, Grant WM. (1977). Carbonic anhydrase inhibitor side effects. Serum chemical analysis. Arch Ophthalmol-chic 95: 1378-82.
11. Everitt DE, Avorn J. (1990). Systemic effects of medications used to treat glaucoma. Ann Intern Med 112:120-5.
12. Ferreira SLC, Bruns RE, Ferreira HS, et al. (2007). Box-Behnken design: an alternative for optimization of analytical methods. Anal Chim Acta 597:179-86.
13. Gohel M, Amin A. (1998). Formulation optimization of controlled release diclofenac sodium microspheres using factorial design. J Control Release 51:115-22.
14. Hitendra SM, Bhushankumar VT, Pankaj PN. (2012). Ondansetron loaded pectin based microspheres for nasal administration: in vitro and in vivo studies. Powder Technol 221:168-76.
15. Ibanoglu S, Ainsworth P. (2004). Effect of canning on the starch gelatinization and protein in vitro digestibility of tarhana, a wheat flour-based mixture. J Food Process Eng 64:243-7.
16. Infeld DA, O'Shea JG. (1998). Glaucoma: diagnosis and management. Postgrad Med J 74:709-15.
17. Jifu H, Xinsheng F, Yanfang Z, et al. (2011). Development and optimization of solid lipid nanoparticle formulation for ophthalmic delivery of chloramphenicol using a Box-Behnken design. Int J Nanomed 6:683-92.
18. Kim MS, Kim JS, You YH, et al. (2007). Development and optimization of a novel oral controlled delivery system for tamsulosin hydrochloride using response surface methodology. Int J Pharm 341: 97-104.
19. Kramar A, Turk S, Vrecer F. (2003). Statistical optimisation of diclofenac sustained release pellets coated with polymethacrylic films. Int J Pharm 256:43-52.
20. Liu D, Jiang S. (2011). Diclofenac sodium-loaded solid lipid nanoparticles prepared by emulsion/solvent evaporation method. J Nanopart Res 13:2375-86.
21. Luo YF, Chen DW, Ren LX, et al. (2006). Solid lipid nanoparticles for enhancing vinpocetine's oral bioavailability. J Control Release 114:53-9.
22. Makoto E, Akitaka M. (2011). Evaluation of dermal and eye irritation and skin sensitization due to carbon nanotubes. Regul Toxicol Pharm 61:278-81.
23. Maren TH. (1967). Carbonic anhydrase: chemistry, physiology and inhibition. Physiol Rev 47:595-781.
24. Maren TH. (1978). Carbonic anhydrase: general perspectives and advances in glaucoma research. Drug Dev Res 10:255-76.
25. Martinez A, Gonzalez F, Capeans C, et al. (1999). Dorzolamide effect on ocular blood flow. Invest Ophth Vis Sci 40:1270-5.
26. Motwani SK, Chopra S, Talegaonkar S, et al. (2008). Chitosansodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: formulation, optimization and in vitro characterization. Eur J Pharm Biopharm 68:513-25.
27. Muller RH, Mader K, Gohla S. (2000). Solid lipid nanoparticles (SLN) for controlled drug delivery: a review of the state of the art. Eur J Pharm Biopharm 50:161-77.
28. Myers RH, Montgomery DC. (2002). Response surface methodology: process and product optimization using designed experiments. New York: John Wiley & Sons, 273-86.
29. Nazzal S, Khan M. (2002). Response surface methodology for the optimization of ubiquinone self-nanoemulsified drug delivery system. AAPS PharmSciTech 3:23-31.
30. Nazzal S, Nutan M, Palamakula A, et al. (2002). Optimization of a selfnanoemulsified tablet dosage form of Ubiquinone using response surface methodology: effect of formulation ingredients. Int J Pharm 240:103-14.
31. Rui Li, Sunmin Jiang, Dongfei Liu, et al. (2011). A potential new therapeutic system for glaucoma: solid lipid nanoparticles containing methazolamide. J Microencapsul 28:134-41.
32. Shah M, Pathak K. (2010). Development and statistical optimization of solid lipid nanoparticles of simvastatin by using 2(3) full-factorial design. AAPS PharmSciTech 11:489-96.
33. Shieh CJ, Koehler PE, Akoh CC. (1996). Optimization of sucrose polyester synthesis using response surface methodology. J Food Sci 61:97-100.
34. Tesch S, Schubert H. (2002). Influence of increasing viscosity of the aqueous phase on the short-term stability of protein stabilized emulsions. J Food Eng 52:305-12.
35. Wissing SA, Kayser O, Muller RH. (2004). Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 56: 1257-72.
36. Woitiski CB, Veiga F, Ribeiro A, Neufeld R. (2009). Design for optimization of nanoparticles integrating biomaterials for orally dosed insulin. Eur J Pharm Biopharm 73:25-33.
37. Yan W, Luyan Z, Zhao D, et al. (2012). Preparation and stability study of norfloxacin-loaded solid lipid nanoparticle suspensions. Colloid Surf B 98:105-11.
38. Ye J, Wang Q, Zhou X, et al. (2008). Injectable actarit-loaded solid lipid nanoparticles as passive targeting therapeutic agents for rheumatoid arthritis. Int J Pharm 352:273-9.
39. Ying L, Pengfei W, Chen S, et al. (2010). Wheat germ agglutiningrafted lipid nanoparticles: preparation and in vitro evaluation of the association with Caco-2 monolayers. Int J Pharm 397: 155-63.
40. Zimmerman TJ. (1978). Acetazolamide and methazolamide. Ann Ophthalmol 10:509-10.
41. Zur Muhlen A, Mehnert W. (1998). Drug release and release mechanism of prednisolone loaded solid lipid nanoparticles. Pharmazie 53: 552-5.